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ARTICLE

OPEN

A single dose of replication-competent VSV-vectored vaccine
expressing SARS-CoV-2 S1 protects against virus replication
in a hamster model of severe COVID-19

1234567890():,;

Delphine C. Malherbe1,2,8, Drishya Kurup 3,8, Christoph Wirblich3,8, Adam J. Ronk1,2, Chad Mire 2,4, Natalia Kuzmina1,2,
Noor Shaik 3, Sivakumar Periasamy 1,2, Matthew A. Hyde2, Julie M. Williams2, Pei-Yong Shi 5,6, Matthias J. Schnell 3,7,9 ✉ and
Alexander Bukreyev 1,2,4,9 ✉
The development of effective countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent
responsible for the COVID-19 pandemic, is a priority. We designed and produced ConVac, a replication-competent vesicular
stomatitis virus (VSV) vaccine vector that expresses the S1 subunit of SARS-CoV-2 spike protein. We used golden Syrian hamsters as
animal models of severe COVID-19 to test the efﬁcacy of the ConVac vaccine. A single vaccine dose elicited high levels of SARS-CoV2 speciﬁc binding and neutralizing antibodies; following intranasal challenge with SARS-CoV-2, animals were protected from weight
loss and viral replication in the lungs. No enhanced pathology was observed in vaccinated animals upon challenge, but some
inﬂammation was still detected. The data indicate rapid control of SARS-CoV-2 replication by the S1-based VSV-vectored SARS-CoV2 ConVac vaccine.
npj Vaccines (2021)6:91 ; https://doi.org/10.1038/s41541-021-00352-1

The current pandemic of coronavirus-induced disease 2019
(COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 146 million conﬁrmed
cases of human infections worldwide, including over three million
conﬁrmed deaths (as of April 25, 2021)1. A few vaccines have been
approved and many more are being developed, including those
based on mRNA, viral vectors, inactivated virus, and protein
subunits2,3. The main antigen of these vaccines is the full-length
spike (S) protein of SARS-CoV-2, since the virus uses its S protein to
mediate cell entry.
Nonsegmented negative-strand RNA viruses including vesicular
stomatitis virus (VSV), which replicates systemically, represent
highly potent vaccine platforms4. These vaccine platforms are
capable of stably expressing foreign open-reading frames ﬂanked
with transcriptional gene-start and gene-end signals speciﬁc for
the viral vector’s polymerase. A number of vaccine candidates for
Middle East respiratory syndrome coronavirus (MERS-CoV), SARSCoV, SARS-CoV-2, and porcine coronavirus utilized VSV and rabies
virus as vector backbones to express the spike protein as
immunogen5–9. We previously developed a MERS vaccine
candidate in which the S1 domain of the MERS spike protein
was fused to the C-terminal part of the rabies virus glycoprotein to
allow incorporation and display on the surface of virions9. We
reasoned that removal of the S2 domain should steer the immune
response toward the receptor-binding domain that is located in
the S1 domain and is the target of neutralizing antibodies. To
expedite COVID-19 vaccine development, we took this proven
strategy to generate a SARS-CoV-2 vaccine candidate in which the
S2 domain was replaced with the C-terminal part of the VSV

glycoprotein as a membrane anchor and expressed in a
replication-competent VSV vector.
We assessed the immunogenicity and efﬁcacy of our vaccine in
the recently established golden Syrian hamster model of COVID1910–12. Golden Syrian hamsters are susceptible to intranasal
infection with wild-type SARS-CoV-2 without the need for virus
adaptation, and develop severe clinical manifestations similar to
those observed in human COVID-19 patients with a severe
disease10–12.

RESULTS
Design and development of the VSV-SARS-CoV-2 vaccine
ConVac
To design our ConVac vaccine construct, we decided to use only
the S1 domain of SARS-CoV-2 spike S for several reasons. First, the
S1 region contains the necessary neutralizing epitopes with the
receptor-binding domain being most important13. Second, both
prefusion and postfusion S2 structures present potential drawbacks as vaccine constructs, and vaccines expressing the fulllength S-spike protein may generate both prefusion and postfusion spikes as observed in in vitro mammalian cell culture
production systems14. Because of its high level of glycosylation it
has been proposed that the S2 postfusion conﬁguration may act
as an immunological decoy by eliciting immunodominant
nonneutralizing responses while stabilization of prefusion S2
may affect bonds between protomers thus affecting the overall
trimer stability14. The third reason for the use of the S1-only
approach is that the S2 domain is more conserved between
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Fig. 1 Generation and characterization of ConVac. a Left: genome structure of the VSV vector expressing the membrane-anchored SARSCoV2 S1 domain. The S1 domain of SARS-CoV2 spike protein (aa 1–681) was joined to the C-terminal 70 amino acids of the VSV glycoprotein.
The fusion construct was inserted between the glycoprotein and polymerase genes of VSV. The S1 domain is shown in red and the VSV G tail
in green. The transmembrane domain of the VSV glycoprotein is indicated by a yellow box. The amino acids at the junction between S1 and
VSV glycoprotein are highlighted. Right: schematic representation of the vaccine construct that shows the two transmembrane proteins
anchored in the membrane. b Immunoﬂuorescence staining of Vero E6 cells infected with ConVac and a control virus expressing Hendra virus
G (VSV-HeVG). The cells were ﬁxed and permeabilized 10 h after infection and stained with ﬂuorescently labeled monoclonal antibody CR3022
against the S1 domain (shown in red) and two monoclonal antibodies against the VSV glycoprotein (shown in green). c Western blot analysis
of BSR cells infected with Convac and a control VSV virus expressing GFP. Protein lysates were resolved on 4–20% polyacrylamide-gradient
gels and transferred to nitrocellulose membranes. The membranes were probed with polyclonal antiserum against the S1 domain (upper
panel), monoclonal antibodies against the VSV glycoprotein (middle panel), and a monoclonal antibody against the VSV matrix protein (lower
panel). VSV glycoprotein expression was signiﬁcantly reduced in cells infected with ConVac whereas matrix protein expression was only
modestly affected. d Viral growth curve on Vero cells. The cells were infected at an MOI of 0.05 PFU with ConVac, or VSV-expressing GFP or
another control virus expressing Hendra virus glycoprotein. Supernatants were collected 12, 24, and 36 h post infection and titrated on Vero
E6 cells. Data represent mean ± SD.

different coronaviruses15,16, and we hypothesized that in previously coronavirus-infected humans the immune response might
predominantly target S2 rather than S1. Last, previous research
with a rabies virus-vectored vaccine indicated that the expression
of the full-length coronavirus S protein interfered with the
transport of the rabies virus G protein and reduced vaccine viral
titers dramatically9. Moreover, VSV G-deleted viruses grow to a
lower titer of about 107 PFU, whereas VSV G-containing viruses
can reach titers up to 1–5 × 108, making vaccine production more
efﬁcient17,18. These reasons led us to develop a VSV-based vaccine
construct containing only the membrane-anchored S1 domain by
substituting the S2 domain of the SARS-CoV-2 spike protein with
the C-terminal region of the VSV glycoprotein.
Thus, following the strategy we previously employed to
generate a membrane-anchored S1 domain of MERS9, and we
replaced the S2 domain of SARS-CoV-2 (aa 682–1284) with the Cterminal 70 amino acids of VSV G (Fig. 1a). This portion contains
the complete cytoplasmic tail of the VSV glycoprotein, as well as
the transmembrane domain and a short membrane-proximal
portion of the ectodomain of VSV-G. The VSV-G tail serves as a
membrane anchor for S1 and allows incorporation into VSV
particles. We recovered the virus as described previously19 and
performed immunoﬂuorescence staining with antibodies directed
against S1 or VSV glycoprotein (Fig. 1b). Vero cells infected with
ConVac expressed both S1 and VSV glycoprotein. No S1 signal was
detected in cells infected with a control virus expressing Hendra
virus G. We also performed western blotting to assess protein
expression (Fig. 1c, S1). Using polyclonal antiserum directed
against the S1 domain we detected a protein of 160 kDa and a
shorter band of approximately 100 kDa. The smaller band
presumably represents unglycosylated or partially glycosylated
npj Vaccines (2021) 91

protein, whereas the larger band represents the fully glycosylated
mature protein. VSV glycoprotein expression was noticeably
reduced compared with the control virus-expressing GFP. To
assess the impact on viral replication, we evaluated growth
kinetics in Vero cells (Fig. 1d). ConVac grew to titers 2–4 × 108 FFU/
ml, which are about ﬁve-fold lower than the control virus
expressing-GFP and modestly lower compared with a recombinant VSV-expressing Hendra virus G. Similar titers were obtained
in human lung and baby hamster kidney cells (data not shown).
Development of the hamster model of COVID-19
To determine if golden Syrian hamsters are a suitable animal
model to study the protective efﬁcacy of the vaccine, eight female
golden Syrian hamsters were infected intranasally with 105 PFU of
SARS-CoV-2 strain USA-WA1/202020 at day zero in a volume of
100 µl, and four female hamsters were mock-infected with 100 µl
of phosphate-buffered saline. Animals were monitored daily for
weight loss (Fig. 2a). Viral load determination in the lungs (Fig. 2b)
and nasal turbinates (Fig. 2c) was performed two and four days
post challenge. At day four, SARS-CoV-2-infected hamsters had
lost an average of 7.3% of their initial body weight, while mockinfected animals did not display any weight loss (Fig. 2a). Viral
loads were both higher in the lungs (mean viral load of 3.0 × 106
PFU/g) and in the nasal turbinates (2.7 × 106 PFU/g) at day two
compared with day four (3.4 × 105 PFU/g of lung and 4.1 × 104
PFU/g nasal turbinate) (Fig. 2b, c). Lung histopathological changes
were assessed in two animals of each group at each time point
(criteria displayed in Supplementary Table 121). The SARS-CoV-2infected hamsters displayed lung pathology consistent with
typical interstitial pneumonia at both time points (Fig. 2d), while
some alveolar changes and septal thickening (Fig. 2i) were also
Published in partnership with the Sealy Institute for Vaccine Sciences
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Fig. 2 Pathogenicity and replication of SARS-CoV-2 in golden Syrian hamsters. Hamsters were challenged intranasally with 105 PFU SARSCoV-2 at day zero and monitored for four days. a % change in body weight. Data represent mean ± SEM. SARS-CoV-2 group is shown in black,
and mock infected group in blue. Viral loads were determined in lung b and nasal turbinate c tissues two and four days post challenge. Right
lungs and nasal turbinates from each animal were homogenized in media and titrated on Vero E6 cells. No virus was detected in the mockinfected animals (data not shown). N = 4 for mock-control group (two hamsters euthanized at each timepoint) and N = 8 for VSV vaccine
group (four hamsters euthanized at each timepoint). Comparative pathology scores for lungs from SARS-CoV-2-infected and mock-infected
hamsters (two animals in each group) were determined 2 days (D2) and 4 days (D4) post challenge (d–h). Scores for overall lung pathology (d),
and individual criteria including consolidation or extent of inﬂammation (e), type of inﬂammatory foci (f), airway pathology (g) and septal
thickening (h) are displayed. The pathology scores (mean) were calculated based on the criteria described in Supplementary Table 1. Data
represent mean ± SD, N = 2 for each group at each timepoint. i Day four mock-infected lung displaying minimal pathologic changes in
airways. Note a septal thickening and alveolar wall damage (likely due to CO2 euthanasia). j Day four SARS-CoV-2-infected lung displaying
widespread inﬂammatory change, septal thickening, and airway inﬁltration. Scale bars are 1 mm.

observed in the mock-infected animals that were a consequence
of the CO2 euthanasia method used in this pilot study. In SARSCoV-2-infected hamsters, widespread inﬂammatory changes consisting of small-to-large inﬂammatory foci were observed (Fig. 2e,
f). In addition, inﬁltration of airways with inﬂammatory cells (Fig.
2g, j) and a moderate level of inter-alveolar septal thickening were
noted in SARS-CoV-2-infected animals (Fig. 2h, j). Thus, lung
pathology observed in our pilot study indicates that the golden
Syrian hamster is a suitable animal model reproducing the typical
interstitial pneumonia caused by SARS-CoV-2 in humans. In
addition, our ﬁndings are in agreement with others as while this
paper was in preparation, other teams reported that SARS-CoV-2
infection of hamsters causes a severe lung disease, with viral
replication in the upper and lower respiratory tract10–12.
ConVac vaccine induces a robust antibody response
The immunogenicity and efﬁcacy of the ConVac vaccine was
evaluated in the golden Syrian hamster animal model. Hamsters at
Published in partnership with the Sealy Institute for Vaccine Sciences

12 animals per group were vaccinated once intramuscularly on
day zero (Fig. 3a) with 2 × 107 FFU/animal of ConVac, while the
control group remained naive. On day 10 post vaccination, one
vaccinated hamster was euthanized due to hind-leg paralysis, and
on day 11, another hamster was found dead after being lethargic,
scruffy, hunched and with heavy breathing the day before. All
other animals demonstrated no disease symptoms. At day 31,
vaccinated and control hamsters were challenged intranasally
with a dose of 105 PFU of the SARS-CoV-2 isolate USA-WA1/
202020. Serum samples were assayed longitudinally to determine
SARS-CoV-2 S1-speciﬁc binding antibody responses. Testing of the
binding to puriﬁed S1 protein demonstrated induction of IgG EC50
titers ranging from 1:505 to 1:5096 with a mean titer of 1:2279 on
day 28 after vaccination (Fig. 3b). One control animal demonstrated the presence of SARS-CoV-2 antibodies by ELISA, but was
negative for SARS-CoV-2-neutralizing antibodies. All vaccinated
animals demonstrated induction of S1-binding Th1-speciﬁc IgG2/3
with titers ranging from 1:39 to 1:285 and a mean titer of 1:139
npj Vaccines (2021) 91
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Fig. 3 ConVac elicits SARS-CoV-2 S1-speciﬁc binding and neutralizing antibodies. a Study schedule. Sera collected during the
immunogenicity phase (days minus one and day 28) and the challenge phase (day 34 is three days post challenge and day 46 is 15 days post
challenge) were assessed for their ability to bind to SARS-CoV-2 spike protein S1 and to neutralize SARS-CoV-2. b, c Antibody responses
determined by ELISA: total IgG (b) and IgG2/3 (c) displayed with a line at mean ± SEM and P values determined by Kruskal–Wallis test, followed
by Dunn’s multiple comparison. d Neutralization of the USA-WA1/2020 virus at day 28 displayed as mean ± SEM. A plasma sample from a
COVID-19 convalescent human subject was included as positive control. e Longitudinal 50% neutralization titers against the USA-WA1/2020
virus with line at mean ± SEM with P values determined by Kruskal–Wallis test, followed by Dunn’s multiple comparison. f Neutralization of the
UK (B.1.1.7) virus by day-28 serum samples, with line at mean. P value determined by Mann–Whitney test. g Comparison of neutralization of
the USA-WA1/2020 virus and the UK (B.1.1.7) virus shown for individual animals. P value for ConVac determined by Mann–Whitney test.

(Fig. 3c), mirroring the total IgG responses albeit at a lower level.
Both total IgG and IgG2/3 S1-speciﬁc binding antibody titers were
signiﬁcantly higher in the vaccinated animals compared with the
control animals, which displayed detectable antibody levels after
the challenge (Fig. 3b, c). IgG1 was not analyzed due to the lack of
a suitable secondary antibody for hamster IgG1. Neutralization of
SARS-CoV-2 USA-WA1/2020 was assessed with the recombinant
SARS-CoV-2-expressing Neon Green protein (SARS-CoV-2-mNG)22
using the ﬂuorescent signal as a readout for viral replication, thus
enabling a fast and quantitative evaluation. Neutralization curves
showed similar levels of SARS-CoV-2 antibodies in ConVacvaccinated animals and a human COVID-19 survivor (Fig. 3d).
After the single immunization, the ConVac vaccine elicited 50%
SARS-CoV-2-neutralizing titers ranging from 1:85 to 1:886 with the
mean titer of 1:369. After the challenge, the levels of neutralizing
antibodies were signiﬁcantly higher in the vaccinated group
npj Vaccines (2021) 91

compared with the control group (Fig. 3e). The SARS-CoV-2
challenge did not elicit an anamnestic antibody response in the
ConVac-vaccinated animals, as the binding and neutralizing
antibody titers did not increase between the time points before
and after the challenge (day 28 vs 34 and day 28 vs 46, P > 0.05 for
both comparisons for total IgG, IgG2/3, and neutralizing antibodies, Wilcoxon test). In addition, elicitation of neutralizing
antibodies against the United Kingdom (UK) (lineage B.1.1.7)
SARS-CoV-2 variant was assessed with the recombinant SARS-CoV2 USA-WA1/2020 virus engineered to express the spike protein of
this virus23. Neutralizing antibody titers against the B.1.1.7 UK virus
were detected in all tested animals (Fig. 3f). In comparison with
the USA-WA1/2020 virus, the difference in neutralization titers of
the B.1.1.7 UK virus ranged from zero to a six-fold decrease
(Fig. 3g). Taken together, our data show that a single-vaccine dose
induced a robust SARS-CoV-2-speciﬁc antibody response.
Published in partnership with the Sealy Institute for Vaccine Sciences
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Fig. 4 Hamster body weight change and health scores upon SARS-CoV-2 infection. Hamsters were vaccinated at day zero and challenged
intranasally with 105 PFU SARS-CoV-2 at day 31. a % change in body weight and b individual disease score. Data represent mean ± SEM. VSV
vaccine is shown in red and control group in black. N = 12 for control group (six hamsters euthanized at day three post challenge) and N = 10
for ConVac group (ﬁve hamsters euthanized at day three post challenge). Body weight P value determined by Wilcoxon test.

Fig. 5 SARS-CoV-2 tissue viral load in hamsters. Hamsters were challenged intranasally with 105 PFU SARS-CoV-2 and half of the animals in
each group were euthanized at days three and 15 post challenge. Right lungs (a, c) and nasal turbinates (b, d) from each animal were
homogenized in media, and viral loads were determined by plaque assays on Vero E6 cells (a, b) or by qRT-PCR (c, d). The limit of detection for
the plaque assay was 70 PFU per lung and 35 PFU per nasal turbinate. The limit of detection for the qRT-PCR assay is indicated by the dotted
line. The ConVac vaccine group is shown in red and the control group in black. For each timepoint, N = 6 for control group and N = 5 for
ConVac vaccine group. Mean values ± SEM. P values determined by Mann–Whitney test.

ConVac vaccine signiﬁcantly decreases SARS-CoV-2 viral load
in the lungs
After the challenge, the hamsters were monitored for 15 days.
Animals were checked daily for body weight and clinical signs of
disease. In the control group, a signiﬁcant loss of weight
compared with the vaccine group (P = 0.0002) was detected,
and at the peak of weight loss, which occurred at day ﬁve, the
average weight loss was 9.1% (Fig. 4a). None of the control or the
vaccinated animals reached moribund state, but several control
animals had higher disease scores due to a weight loss greater
than 10% of their initial body weight (Fig. 4b).
On days three and ﬁfteen post challenge, half of the hamsters in
each study group were euthanized, and lungs and nasal turbinates
were harvested to determine viral loads by plaque-reduction assay
(Fig. 5a, b) and the number of viral copies by RT-qPCR assay (Fig.
5c, d). In the control group three days post infection, high virus
load was detected in the lungs of all animals (Fig. 5a), ranging
from 6.5 × 105 PFU/g to 2.5 × 106 PFU/g, and in the nasal
turbinates of all but one animal ranging from 4.0 × 102 PFU/g to
1.2 × 104 PFU/g (Fig. 5b). In contrast, no virus was detected in the
lungs of four out of ﬁve vaccinated hamsters, while the remaining
one had the viral titer 645-fold less than in the control group.
Published in partnership with the Sealy Institute for Vaccine Sciences

No virus was detected in the nasal turbinates of two vaccinated
animals, while the three remaining animals displayed titers
reduced by 57-fold compared with the control animals. On day
15, no SARS-CoV-2 was detected in lungs and nasal turbinates of
both the control and the vaccinated hamsters (Fig. 5a, b).
RNA isolated from the lungs and nasal turbinate homogenates
were assessed for the presence of viral RNA copies by RT-qPCR
assay (Fig. 5c, d). In the control group, high-virus RNA copies were
detected in the lungs and nasal turbinates of animals with ~ 1 ×
1011 RNA copies/g on day three post challenge, ~ 1 × 107 RNA
copies/g in the lung and ~ 6 × 107 RNA copies/g in the nasal
turbinates on day 15 post challenge. In contrast, signiﬁcantly
lower viral RNA copies were detected in the ConVac-vaccinated
animals with ~ 7 × 107 RNA copies/g in the lungs and ~ 1 × 1010
RNA copies/g in the nasal turbinates on day three post challenge,
~ 3.6 × 106 RNA copies/g in the lungs, and ~ 5 × 106 RNA copies/g
in the nasal turbinates on day 15 post challenge. We assume that a
portion of the detected viral RNA on day three is residual input
challenge virus as it was below the detection limit of the plaque
assay. In addition, the detected viral RNA on day 15 post challenge
is not derived from viable viral particles since no plaques were
detected.
npj Vaccines (2021) 91
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Fig. 6 SARS-CoV2 lung pathology. Representative histological images of SARS-CoV-2 infection in control and vaccinated hamster lungs. Left
panels: low magniﬁcation, right panels: higher magniﬁcation of selected regions, indicated by asterisks (yellow) on low-magniﬁcation images.
a, b Day-3 control: widespread consolidation and inﬂammatory inﬁltration is clearly visible, along with obstruction of airways by inﬂammatory
cells. Higher magniﬁcation illustrates airway inﬁltration by mononuclear cells, septal thickening and airway occlusion. c, d Day-3 ConVac
vaccine: moderate inﬂammatory changes with mononuclear cellular inﬁltration, septal thickening, and mild airway pathology. Higher
magniﬁcation illustrates focal inﬁltration by inﬂammatory cells. e, f Day-15 control: typical interstitial pneumonic changes, endothelial damage
and septal thickening. Higher magniﬁcation illustrates endothelial damage and airway epithelia hyperplasia. g, h Day-15 ConVac vaccine:
moderate interstitial pneumonia with septal thickening and endothelial damage. The magniﬁed image illustrates airway cellular inﬁltration
and endothelial damage. Scale bars are 1 mm in the left panels and 0.1 mm in the right panels.

Vaccinated animals do not demonstrate enhanced lung
pathology upon challenge
Pathology scores were determined in a blinded manner in lung
sections of control and vaccinated animals on days three and 15
post challenge. Interstitial pneumonic changes and septal
thickening were noted in control and vaccinated animals (Figs. 6
and 7). On day three, the control group (Fig. 6a, b) showed
widespread inﬂammatory changes and obstruction of airways by
inﬂammatory cells, while the ConVac vaccine group (Fig. 6c,d)
had moderate inﬂammatory changes, septal thickening, and
mild airway pathology. On day 15 (Fig. 6e, f), the control
unvaccinated group displayed typical interstitial pneumonic
changes and endothelial damage, while the ConVac vaccine
group (Fig. 6g, h) displayed interstitial pneumonia with septal
thickening and reduced mononuclear cellular inﬁltrates in airways.
A semiquantitative comparison (Fig. 7) of the control and
vaccinated animals demonstrated no enhanced pathology in the
vaccinated group (P > 0.05 for all panels, Mann–Whitney test).
npj Vaccines (2021) 91

DISCUSSION
The VSV vaccine platform has several features that make it a
strong candidate for further development. These include the
ability to stably express an inserted foreign open-reading frame,
the robust replication resulting in a high immunogenicity, and the
lack of preexisting immunity in the human population. VSVvectored vaccine candidates have been developed against several
human pathogens24, including Ebola virus; in 2019, the VSVvectored vaccine Ervebo was approved by the European
Medicines Agency and the FDA. Here we designed and developed
a VSV-based SARS-CoV-2 vaccine ConVac and tested it for
immunogenicity and efﬁcacy in the hamster model of COVID-19.
The ConVac vaccine elicited a robust humoral response and
protected hamsters from SARS-CoV-2 replication in the lower
respiratory tract. A single dose of ConVac elicited strong SARSCoV-2 S1-binding and virus-neutralizing antibody titers. Importantly, the ConVac vaccine induced neutralizing antibodies against
the B.1.1.7 virus (the UK variant), a result consistent with the data
Published in partnership with the Sealy Institute for Vaccine Sciences
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Fig. 7 Comparative pathology scores for lungs from vaccinated and control hamsters post SARS-CoV-2 challenge. Scores at three days
(a-e) and 15 days (f–j) post challenge. Scores for overall lung pathology (a, f), and individual criteria, including consolidation or extent of
inﬂammation (b, g), type of inﬂammatory foci (c, h), airway pathology (d, i) and septal thickening (e, j), are displayed. The pathology scores
(mean) were calculated based on the criteria described in Supplementary Table 1. The ConVac vaccine group is shown in red and the control
group in black. Data represent mean ± SD, N = 6 for control group and N = 5 for ConVac vaccine group at each time point.

obtained with other vaccine candidates, including the mRNA
vaccines BNT162b2 from Pﬁzer23 and mRNA-1273 from Moderna25. We note that two vaccinated animals were euthanized on
days 10 and 11 after immunization (i.e., prior to the SARS-CoV-2
challenge) due to a disease of unknown etiology; however, we
cannot completely exclude a residual neurovirulence of VSV G at
the high, 2 × 107 FFU, vaccine dose used in our study. SARS-CoV-2
viral loads determined by plaque assay in lung tissues were
signiﬁcantly reduced in ConVac-vaccinated animals compared
with controls, with only one vaccinated hamster having detectable
viral loads on day three, suggesting that the ConVac vaccine
prevents or strongly reduces SARS-CoV-2 replication in the lower
respiratory tract. The hamster with the detectable viral load on day
three had the lowest neutralizing antibody titer. Viral loads in the
nasal turbinate tissues of vaccinated hamsters were reduced
compared with control animals, but the difference was not
statistically signiﬁcant due to the limited number of animals per
group and high variability between samples. Viral RNA levels
determined by RT-qPCR conﬁrmed these ﬁndings of a more
robust protection in the lung compared with the nasal turbinates.
Published in partnership with the Sealy Institute for Vaccine Sciences

These data suggest that ConVac elicited an immune response to
effectively control the viral load.
Two recent studies used G gene-deleted VSV vaccine constructs
expressing full-length SARS-CoV-2 S protein in mice and
hamsters26,27, the same approach as used by Merck, which
recently discontinued the development of SARS-CoV-2 vaccine
candidate V590 due to its low immunogenicity in humans28. In
contrast to this strategy, we used only the S1 subunit of the
protein because it contains the necessary neutralizing epitopes
with that in the receptor-binding domain being highly protective13, and both prefusion and postfusion S2 conformations
present potential drawbacks as vaccine constructs14. Furthermore,
unlike the S1 protein, the S2 subunit is more conserved between
coronaviruses possibly leading to predominant S2-speciﬁc
responses in humans previously infected with heterologous
coronaviruses. Indeed, while cross-neutralizing antibodies targeting S2 have been identiﬁed in SARS-CoV-2-positive and -negative
patient sera29–31, these have not been shown yet to prevent or
treat COVID-19 in contrast to S1-speciﬁc monoclonal treatments32,33. The 50% mean-neutralizing titer induced at day 28
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by our vaccine, 1:369, was higher than the titer of 1:173 elicited by
the other VSV vaccine candidate assessed in hamsters by
Yahalom-Ronen et al.27. When tested in mice, one of these
vaccines elicited mean- and median-neutralizing titers greater
than 1:5000 after two vaccine doses but the median neutralization
titer after one vaccine dose was only 1:5926. The difference in the
immunogenicity can also be explained by differences in growth
kinetics and tissue tropism between a G-deleted VSV and a Gcontaining virus with the latter growing faster, having a broader
tropism in vivo and targeting additional types of immune cells.
Side-by-side comparisons would be needed to elucidate this
further.
We used the hamster model of COVID-19, which does not
require SARS-CoV-2 adaptation, exhibiting high viral titers and
severe pathologic changes in the lungs10–12, and therefore seems
to reproduce a severe form of COVID-19 observed in humans.
Indeed, we conﬁrmed that SARS-CoV-2 intranasal infection of
hamsters results in viral replication in the upper and lower
respiratory tract. Our data are in agreement with Imai et al.10, who
showed higher viral loads in lungs than in nasal turbinates
whereas Chan et al. observed the opposite results11. Observed
lung histopathological damage was consistent with the changes
described by others as this paper was in preparation10–12.
Therefore the golden Syrian hamster represents an excellent
model of a severe COVID-19 suitable for vaccine testing.
Besides hamsters, several animal models have been developed
for COVID-19. These include the mouse model with the mouseadapted SARS-CoV-234,35, transgenic mice expressing human
angiotensin-converting enzyme 2 (ACE-2)36, mice infected with a
replication-defective Ad5 adenovirus expressing ACE-2 (Ad5hACE2) transiently37, and the NHP model of COVID-1938. The
mouse-adapted strains of SARS-CoV-2, despite reaching the titers
of 106 PFU/g or 108.3 viral RNA copies per gram of lung tissue,
caused only mild-to-moderate lung disease34,35. In the Ad5-hACE2
transduced mice, SARS-CoV-2 replicated in the lungs reaching 106
PFU/g and caused a lung pathology consistent with a severe
pneumonia37. Transgenic mice expressing human ACE2 supported
SARS-CoV-2 replication in the lungs (106.8 copies/ml) and
developed moderate interstitial pneumonia36. In Rhesus macaques, SARS-CoV-2 replicated in the lungs reaching 105–108 copies/
g but induced only mild-to-moderate interstitial pneumonia38.
Thus, the levels of pathology induced by SARS-CoV-2 in the
available animal models vary signiﬁcantly from very mild to severe
with the hamster representing a model of a severe disease,
potentially explaining some residual lung pathology observed in
the ConVac-vaccinated hamsters. Indeed, we propose that despite
the lack of detectable viable SARS-CoV-2 by plaque assay, the
observed pathologic changes in ConVac-vaccinated hamsters are
likely to be related to the extremely high susceptibility of hamsters
to SARS-CoV-2 on one hand and the very robust immune response
to the vaccine on the other. Upon intranasal challenge, binding to
cells of the epithelium of the respiratory tract and possibly some
very limited replication, the virus is likely to be neutralized by the
high levels of antibodies, resulting in the inﬂux of Fc-bearing
immune cells including lymphocytes and macrophages. Importantly, while some pathologic changes were observed in
vaccinated animals, no enhancement compared with the control
group was detected. Furthermore, testing of a vaccine in different
animal models (mouse, hamster, ferret, and NHP) with various
levels of susceptibility to SARS-CoV-2 is likely to result in a more
realistic prediction of the outcome of vaccination and subsequent
infection in humans.
In conclusion, our data show that the VSV-vectored SARS-CoV-2
vaccine based only on the S1 subunit induces a high titer of
serum-neutralizing antibodies and protects hamsters from SARSCoV-2 replication in the lower respiratory tract without causing an
enhanced disease.
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METHODS
Antibodies
Monoclonal antibody CR3022 was produced by transient transfection of
293 F cells with cDNA expression plasmids obtained from BEI resources.
The cells were transfected at a density of approximately 2 × 106 cells/ml
with equal amounts of each plasmid using Expifectamine reagent (Thermo
Fisher) according to the instructions provided by the manufacturer. The
supernatant was harvested after 4–5 days and antibody puriﬁed on Protein
G Sepharose (Abcam, GE Healthcare) following standard protocols.
Monoclonal antibodies I1 and I14 against the VSV glycoprotein and
monoclonal antibody 23H12 against the VSV matrix protein were puriﬁed
from hybridoma supernatant by afﬁnity chromatography on Protein G
sepharose. The antibodies were labeled with ﬂuorophores using Dylight
antibody labeling kits from Thermo Fisher. The following SARS-CoV-2speciﬁc human monoclonal antibodies were kindly provided by Distributed Bio: DB_A03-09, 12; DB_B01-04, B07-10, 12; DB_C01-05, 07, 09, 10;
DB_D01, 02; DB_E01-04, 06, 07; DB_F02-03.

Generation of ConVac vaccine
Codon-optimized cDNA encoding the SARS-CoV-2 S1 domain fused to the
C-terminal portion of the VSV glycoprotein was obtained from Genscript.
The cDNA was cloned into the XhoI and NheI sites of a modiﬁed
recombinant VSV vector containing an additional transcription start–stop
signal between the G and L genes9. The recombinant virus was recovered
on 293 T cells as described previously, ﬁltered through a 0.22-µm ﬁlter and
used to inoculate Vero (CCL-81, ATCC) or human BEAS-2B lung cells (gift
from R. Plemper, University of Georgia). The infected cells were cultured in
serum-free VP-SFM or Optipro medium. Cell culture supernatant was
harvested three days post inoculation, ﬁltered through 0.45-um PES
membrane ﬁlters and used for virus characterization and animal
experiments.

Characterization of the ConVac vaccine
Baby hamster kidney (BSR) cells were inoculated with ConVac or VSV
control virus expressing GFP at an MOI of 0.2 PFU. The following day, cells
were lysed in detergent buffer (1% TritonX-100, 0.4% sodium deoxycholate, 150 mM NaCl, 20 mM HEPES, pH 7.0, and 1 mM EDTA) supplemented
with a protease inhibitor cocktail (Thermo Fisher). Protein concentration
was determined by BCA assay (Thermo Fisher), and ten micrograms of total
protein were resolved on 4–20% Tris-Glycine gels (Thermo Fisher). The
proteins were transferred to nitrocellulose membranes and probed with
polyclonal rabbit serum against SARS-CoV S1 domain (Thermoﬁsher, Cat
No. PA5-81798 and PA5-81795), monoclonal antibodies I1 (8G5F11) and I14
(IE9F) against the VSV glycoprotein, and monoclonal antibody 23H12
against VSV matrix protein provided by Douglas Lyles (Wake Forest
University). After incubation with HRP-conjugated anti-rabbit or antimouse IgG (Jackson Immunoresearch), the membrane was incubated with
WestDura substrate (Thermo Fisher), and bands were visualized on a
Fluochem M imager (Biotechne). All blots shown in Fig. 1c were derived
from the same experiment and processed in parallel.
For immunoﬂuorescence staining, Vero E6 cells were seeded on
coverslips and infected at three different MOI ranging from 0.01 to 0.1
PFU. After 10 h, the cells were ﬁxed for 10 min in Cytoﬁx/Cytoperm (Becton
Dickinson) and permeabilized for 10 min in 0.5% Tween 20 in Dulbecco
phosphate-buffered saline (DPBS). After washing with DPBS, the cells were
incubated for 2 h with monoclonal antibody CR3022 conjugated to Dylight
550 or a mixture of monoclonal antibodies I1 and I14 conjugated to
Dylight 488. Coverslips were washed in DPBS and mounted using Prolong
Glass (Thermo Fisher). Images were acquired on a Zeiss Axioskop40
microscope equipped with a ProgresCF digital camera.
To assess viral replication of ConVac in vitro, Vero (CCL-81) cells were
seeded in 6-well plates and infected the next day at 34 °C at an MOI of ﬁve
and 0.05 PFU. After 1.5 h the inoculum was removed the cells were washed
3x in DMEM and fresh medium containing 2% FCS was added to each well.
The supernatant was collected at various time points from 6 to 36 h post
infection. A tenfold serial dilution of supernatant was prepared in DMEM
medium in a 96-well plate. The diluted supernatant was added to Vero E6
cells seeded in 96-well plates the day before. After 24 h of incubation at
34 °C, the cells were ﬁxed with 80% acetone and stained with ﬂuorescently
labeled monoclonal antibody 23H12 against the VSV matrix protein.
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Viruses

Neutralizing antibody response

The SARS-CoV-2 challenge strain used in this study is the ﬁrst U.S. isolate
SARS-CoV-2 USA-WA1/2020 from the Washington State patient identiﬁed
on January 22, 202020. Passage 3 was obtained from the World Reference
Center for Emerging Viruses and Arboviruses (WRCEVA) at UTMB. Virus
stocks were propagated in Vero E6 cells. The challenge stock used in this
study is passage 5. The recombinant SARS-CoV-2-expressing Neon Green
protein (SARS-CoV-2-mNG)22 used in the neutralization assay was
developed by Dr. Pei-Yong Shi at UTMB. Virus stocks were propagated in
Vero E6 cells and passage 4 was used in this study. The recombinant USAWA1/2020 SARS-CoV-2 viruses expressing the spike protein of the United
Kingdom variant (B.1.1.7) used in neutralization assays were developed in
our previous study23. Virus stocks were propagated in Vero E6 cells, and
passage-1 stocks were used for neutralization assays.

Sera collected from animals were tested for neutralizing capabilities
against SARS-CoV-2. Neutralization assay medium is MEM (Gibco)
supplemented with 2% FBS (Gibco), 50 µg/ml gentamicin sulfate (Corning)
and 5 mM Hepes buffer (Corning). Brieﬂy, serum samples were heatinacitvated (30 min at 56 °C). Tenfold diluted sera were further diluted in a
2-fold serial fashion, and 60 µl of each serum dilution was mixed with 60 µl
of SARS-CoV-2-mNG (200 PFU)22. The serum/virus mixtures were incubated
for 1 h at 37 °C. About 100 µl of the serum/virus mixtures were then
transferred to Vero E6 cell monolayers in ﬂat-bottom 96-well plates and
incubated for two days at 37 °C. Virus ﬂuorescence was measured with a
Cytation Hybrid Multi-Mode reader at 488 nm (Biotek Instruments). For the
neutralization of the UK (B.1.1.7) virus23, nine out 10 serum samples from
the ConVac group and 10 out 12 serum samples from the control group
were available. Serum samples were heat-inactivated (30 min at 56 °C),
diluted 10-fold and further diluted in a 2-fold serial fashion, and 50 µl of
each serum dilution was mixed with 50 µl of virus added for the targeted
number of 50 PFU. The serum/virus mixtures were incubated for 1 h at
37 °C. Fifty µl of the serum/virus mixtures were then transferred to Vero E6
cell monolayers in ﬂat-bottom 96-well plates, incubated for 1 h at 37 °C,
and the serum/virus mixture was replaced with 2:1 overlay composed of
1% methylcellulose (Fisher Chemical) and MEM (Gibco) supplemented with
gentamicin sulfate (Corning) and 4% FBS (Gibco). Plates were incubated
two days at 37 °C, ﬁxed with 10% neutral buffered formalin (Fisherbrand),
and removed from biocontainment. Plates were washed three times with
DPBS (Corning). Plaques were visualized by immunostaining with a primary
antibody cocktail of 37 SARS-CoV-2-speciﬁc human antibodies kindly
provided by Distributed Bio. The primary antibody cocktail was diluted at
2 µg/ml in blotto (DPBS [Corning] with 5% milk), and plates were incubated
for 1 h at 37 °C. Plates were washed three times in 1X DPBS (Corning). As
secondary antibody, HRP-labeled goat anti-human IgG (SeraCare) was used
at dilution 1:500 in blotto and plates were incubated for 1 h at 37 °C. Plates
were washed three times in 1X DPBS (Corning) and plaques were revealed
by a 30-min incubation at 37 °C with AEC substrate (enQuire Bioreagents).

Animal studies
The studies were carried out in strict accordance with the recommendations described in the Guide for the Care and Use of Laboratory Animals of
the National Research Council. UTMB is an AAALAC-accredited institution
and all animal work was approved by the IACUC Committee of UTMB. All
efforts were made to minimize animal suffering and all procedures
involving potential pain were performed with the appropriate anesthetic
or analgesic. The number of hamsters used was scientiﬁcally justiﬁed
based on statistical analyses of virological and immunological outcomes.

Pathogenicity of SARS-CoV-2 in hamsters
On day zero, seven-week-old golden Syrian female hamsters (Envigo) were
anesthetized with ketamine/xylazine, and eight animals were exposed
intranasally to the targeted dose of 105 PFU of SARS-CoV-2 in a volume of
100 µl, while four animals were mock-infected with 100 µl of 1X DPBS.
Animals were monitored daily for weight loss and signs of disease. Half of
the animals in each group (four SARS-CoV-2-infected and two mockinfected hamsters) were euthanized by CO2 inhalation for viral load
determination two and four days post challenge. Lungs collected on days
two and four from two animals in each group were stored in 10% formalin
for histopathological assessment (see below).

Vaccination and SARS-CoV-2 challenge
Seven-week-old golden Syrian female hamsters (Envigo) were anesthetized
with 5% isoﬂurane prior to immunization and blood collections and with
ketamine/xylazine prior to the SARS-CoV-2 challenge. On day zero, the
vaccine group (N = 12 animals) was inoculated with 2 × 107 FFU of ConVac
in 100 µl of injection volume via the intramuscular route (50 µl per hind
leg), while the control group (N = 12 animals) remained naive. Vena cava
blood collections were performed one day prior to the immunization and
on day 28 afterward. On day 31, vaccinated and control animals were
exposed intranasally to the targeted dose of 105 PFU of isolate SARS-CoV-2.
Animals were monitored daily for weight loss and signs of disease. Half of
the animals in each group (ﬁve vaccinated and six control hamsters) were
euthanized by overdose of injectable anesthetics three days post challenge
for viral load determination. The remaining animals were euthanized
15 days post infection by overdose of ketamine/xylazine.

Binding antibody response
To determine antibody responses to the S protein of SARS-CoV-2, an
indirect ELISA was developed utilizing puriﬁed S1 protein. The soluble S1
protein was produced by transfecting 293 T cells with a plasmid that
expresses a secreted S1 ectodomain (aa 16–681) fused to the C-terminal
HA tag. Puriﬁcation of the HA-tagged protein from the supernatant of
transfected cells was carried out as described previously19. Antibody
responses to SARS-CoV-2 spike protein (S1) were measured by an indirect
ELISA as described previously19. Brieﬂy, wells were coated overnight at 4 °C
with 500 ng/mL of S1-recombinant protein. The secondary antibodies used
in the ELISA are HRP-conjugated goat anti-syrian hamster IgG secondary
antibody (Jackson immunoresearch, Cat# 107-035-142, 1:8000 in PBST) or
mouse anti-hamster IgG2/3-HRP (Southern Biotech, Cat# 1935-05, 1:8000 in
PBST). Optical density was measured at 490 nm and 630 nm using an
ELX800 plate reader (Biotek Instruments). Data were analyzed with
GraphPad Prism (Version 8.4.3) using 4-parameter nonlinear regression.
Published in partnership with the Sealy Institute for Vaccine Sciences

Tissue processing and viral load determination
For the pathogenicity study, animals from each study group were
euthanized on days two and four post challenge, and the lungs and nasal
turbinates were harvested. For the vaccine study, animals were euthanized
on days three and 15 post challenge, and the lungs and nasal turbinates
were harvested. For both studies, right lungs and nasal turbinates were
placed in L15 medium supplemented with 10% fetal bovine serum (Gibco)
and Antibiotic-Antimycotic solution (Gibco), ﬂash-frozen in dry ice, and
stored at −80 °C until processing. Tissues were thawed and homogenized
using the TissueLyser II system (Qiagen). Tissue homogenates were titrated
on Vero E6 cell monolayers in 24-well plates to determine viral loads. Plates
were incubated three days at 37 °C before being ﬁxed with 10% formalin
and removed from containment. Plaques were visualized by immunostaining with 1 µg/mL cocktail of 37 SARS-CoV-2-speciﬁc human antibodies
kindly provided by Distributed Bio. As the secondary antibody, HRP-labeled
goat anti-human IgG (SeraCare) was used at dilution 1:500. Primary and
secondary antibodies were diluted in 1X DPBS with 5% milk. Plaques were
revealed by AEC substrate (enQuire Bioreagents).

qRT-PCR
Tissue homogenates were mixed with TRIzol Reagent (Life Technologies) at
a 1:5 volume ratio of homogenate to TRIzol. The RNA extraction protocol
for biological ﬂuids using TRIzol Reagent was followed until the phaseseparation step. The remaining RNA extraction was done using the
PureLink RNA Mini Kit (Ambion). The quantity and quality (260/280 ratios)
of RNA extracted was measured using NanoDrop (Thermo Fisher). SARSCoV-2 nucleoprotein cDNA was generated from RNA from Bei Resources
(NR-52285) by One-Step RT PCR (SuperScript IV, Thermo Fisher) with
primers SARS COV-2 N IVT F1 (5′-GAATTCTAATACGACTCACTATAGGGG
ATGTCTGATAATGGACCC-3′) and SARS COV-2 N IVT R1 (5′- GCTAGCTT
AGGCCTGAGTTGAGTCAGCACTGCT-3′). The SARS-CoV-2 N standards were
generated by in vitro transcription of the generated SARS-CoV-2 N cDNA
using the MegaScript T7 Transcription kit (Invitrogen), followed by using
the MEGAclear Transcription Clean-Up Kit. Aliquots of 2 × 1010 copies/µL
were frozen at −80 °C. Five microliters of RNA per sample were run in
triplicate, using the primers 2019-nCoV_N2-F (5′- TTACAAACATTGGCCGC
AAA-3′), 2019-nCoV_N2-R (5′-GCGCG ACATTCCGAAGAA-3′) and probe
2019-nCoV_N2-P-FAM (5′-ACAATTTGCCCCCAGCGCTTCAG-3′).
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Histopathology
Following euthanasia, necropsy was performed, gross lesions were noted,
and left lungs were harvested in 10% formalin for histopathological
assessment. After a 24-h incubation at 4 °C, lungs were transferred to fresh
10% formalin for an additional 48-h incubation before removal from
containment. Tissues were processed by standard histological procedures
by the UTMB Anatomic Pathology Core, and 4-μm-thick sections were cut
and stained with hematoxylin and eosin. Sections of lungs were examined
for the extent of inﬂammation, type of inﬂammatory foci, and changes in
alveoli/alveolar septa/airways/blood vessels in parallel with sections from
uninfected or unvaccinated lungs. The blinded tissue sections were
semiquantitatively scored for pathological lesions using the criteria
described in Supplementary Table 1. Examination was performed with
an Olympus CX43 microscope at magniﬁcation 40X for general observation
and 100X magniﬁcation for detailed observation. Each section was scored
independently by two trained lab members, and as scores were in
agreement, only one set is presented.

12.
13.
14.
15.

16.
17.

18.

Statistical analyses
Statistical analyses were performed with GraphPad Prism for Windows
(version 6.07). P < 0.05 was considered signiﬁcant.

19.
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Biocontainment work
Work with SARS-CoV-2 was performed in the BSL-3 and BSL-4 facilities of
the Galveston National Laboratory according to approved standard
operating protocols.
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Reporting summary
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Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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